A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer
Clinical trial NCT03429101 · TERMINATED
Trial details
- NCT number
- NCT03429101
- Sponsor
- Spectrum Pharmaceuticals, Inc
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-07-13
- Primary completion
- 2019-04-17
- Enrollment
- 6
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.